Supernus Pharmaceuticals (SUPN) EBT (2011 - 2025)

Supernus Pharmaceuticals (SUPN) has 15 years of EBT data on file, last reported at -$1.9 million in Q4 2025.

• EBT for Q4 2025 came in at -$1.9 million, down 107.25% year-over-year; the trailing twelve-month figure through Dec 2025 was -$49.0 million (down 150.1% YoY), and the FY2025 annual result was -$49.0 million, down 150.1% from the prior year.
• EBT grew to -$1.9 million in Q4 2025 per SUPN's latest filing, from -$58.0 million in the prior quarter.
• Over five years, EBT peaked at $44.9 million in Q3 2024 and troughed at -$58.0 million in Q3 2025.
• A 5-year average of $9.3 million and a median of $10.4 million in 2021 frame the typical range for EBT.
• The sharpest annual moves came in 2024 and 2025: EBT surged 2564.85% in 2024, then sank 2499.59% in 2025.
• A 5-year view of EBT shows it stood at $2.1 million in 2021, then jumped by 1613.31% to $35.1 million in 2022, then plunged by 97.18% to $990000.0 in 2023, then surged by 2564.85% to $26.4 million in 2024, then tumbled by 107.25% to -$1.9 million in 2025.
• Business Quant data shows SUPN's EBT at -$1.9 million in Q4 2025, -$58.0 million in Q3 2025, and $16.7 million in Q2 2025.